Baxter may stay out of Heparin business

Apr 25, 2008

The head of Baxter International Inc. said the company has not decided whether it will resume selling the blood thinner heparin in the United States.

Baxter recalled vials of the drug two months ago after reports of allergic reactions. The U.S. Food and Drug Administration said the drug may have been intentionally contaminated with an animal-like substance to increase supplier profits.

The drug generates $30 million of Baxter's more than $11 billion in annual sales, the Chicago Tribune said Thursday. The newspaper said Wall Street analysts asked Chairman and Chief Executive Robert Parkinson last week if was worth the legal risks to remain in the heparin business.

"We haven't made a decision whether or not we are going to re-enter (the market) with heparin," Parkinson said.

Copyright 2008 by United Press International

Explore further: FDA approves hard-to-abuse narcotic painkiller

add to favorites email to friend print save as pdf

Related Stories

FDA tells doctors new heparin formula less potent

Oct 01, 2009

(AP) -- The Food and Drug Administration is alerting doctors that a widely used blood thinner has been reformulated to improve its safety, though the change could open the door to dosing errors.

Researchers unravel heparin death mystery

Apr 23, 2008

An international team of researchers led by MIT has explained how contaminated batches of the blood-thinner heparin were able to slip past traditional safety screens and kill dozens of patients recently in ...

FDA to test all heparin at U.S. border

Mar 16, 2008

The U.S. Food and Drug Administration has issued an import alert and plans to test all shipments of the drug heparin before they enter the country.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

12 hours ago

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

12 hours ago

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

13 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

13 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments : 0